Articles

As Congress returns, here’s where the Senate could make changes to the GOP’s megabill

The Trump team and House leaders are pushing the Senate to aim for speed rather than lots of revisions to the One Big Beautiful Bill Act.

Stock market’s haul in May comes as tariff turmoil and job angst lurk on the horizon

S&P 500 seizes huge May gains — and lands back on the doorstep of record territory

Amid tariff agita, Wall Street is a bit more cautious than normal on second-quarter earnings

Earnings Watch: Dollar General, Dollar Tree, Victoria’s secret and other retailers report during the week

Why the government’s debt problem is your borrowing problem — but also your opportunity to save

People shopping for a car loan or a mortgage should understand the implications of high bond yields.

Can media company spinoffs of brands like CNN and CNBC be good for investors? Here’s what history tells us.

Recent corporate media spinoffs have been a mixed bag, with many failing due to the way they were set up, Wall Street analysts say.

‘I am getting very frustrated’: My mother’s adviser has not returned my calls. He manages $1 million. Is this normal?

“I am not used to this way of doing business.”

These 3 corporate tax breaks in the Republican megabill look key for investors

As a Republican-run Washington works to enact the party’s big tax and spending package, one key for many businesses has been to revive a trio of tax breaks that they have lost in the last few years.

Trump doubles steel tariffs to 50%, touts U.S. Steel-Nippon deal still short on details

The president said he is doubling duties on steel imports while talking up U.S. Steel’s deal with Japan’s Nippon on Friday.

S&P 500 scores best May since 1990, but stocks end month with fresh tariff worries

U.S. stocks roared back in May as global trade tensions eased, but tariff-related developments around the month’s end suggest a smooth climb from here may be challenging.

‘You are going to panic,’ Jamie Dimon tells regulators about what will happen when the bond market cracks

The bond market is on edge, but less so this week after smooth Treasury auctions and talk of a key banking reform this summer.

Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Marvell tried to ease a big investor concern, but the stock’s slump shows that doubts still linger

Investors still have questions about the computer-chip company’s next-generation custom chips for Amazon and Microsoft.
1 206 207 208 209 210 2,301